Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin
protein-based drugs to target validated disease pathways in a unique and transformative way.
The Roche collaboration, signed in 2015, pursued the discovery of Anticalin
proteins specific for an exploratory immuno-oncology target selected by Roche.
Pieris' proprietary suite of agonistic costimulatory anticalin
proteins, when fused to a tumor-targeting antibody, can activate the immune system preferentially in the tumor microenvironment.
The collaboration and license agreement will see both firms assess novel bispecific immuno-oncology agents that integrate Pieris' anticalin
technology with select Seattle Genetics cancer-targeted antibodies.
By applying a mutation and selection process, it is possible to select Anticalin
proteins that can specifically bind to very diverse protein targets in a monovalent fashion.
Pieris AG and The Sanofi Group have expanded their discovery and development partnership to include a novel multi-specific Anticalin
Pieris can format Anticalin
leads as dual targeting proteins, so-called Duocalins.
(NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin
technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2019 investor call on Thursday, August 1, 2019 at 8:00 AM (EDT) to provide a corporate update.